Cablivi Injection 10mg Drug Use Investigation for patients with aTTP

Cablivi Injection 10mg Drug Use Investigation for patients with aTTP - Cablivi Injection 10mg Drug Use Investigation for patients with aTTP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049385

Enrollment

120

Registered

2022-11-01

Start date

2022-12-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired thrombotic thrombocytopenic purpura

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients treated with Cablivi

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Incidence during the observation period of adverse drug reaction mainly related to the safety specifications	—

Countries

Japan

Contacts

Public ContactMasahiro Tamura

Medical Affairs Post-authorization regulatory studies

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results